RareStone In-Licenses China Rights to Obesity Therapy in $75 Million Deal

RareStone, a Shanghai-Boston rare disease company, in-licensed greater China rights to a therapy for genetic obesity from Rhythm Pharma in a $75 million agreement. Rhythm’s IMCIVREE was approved in the US last year to treat severe, early-onset obesity and hyperphagia caused by the acquired and genetic melanocortin-4 receptor (MC4R) pathway. Founded in 2019 by Eight Roads, F-Prime Capital and Vivo Capital, RareStone completed an $80 million Series A one year ago to develop rare disease therapies in China . It was originally known as Citrine Medicine. More details.... Stock Symbol: (NSDQ: RYTM) Share this with colleagues: // //